<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did CytomX Therapeutics' revenue and expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/7/2025 06:32pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">CytomX Therapeutics' revenue and expenses in Q4 2024 showed a revenue of $38.09 million and total expenses of $18.88 million, with $14.79 million being R&amp;D expenses.


|code|Ticker|Name|Date|R&amp;D Expenses|Total Revenue|Net Income|market_code|
|---|---|---|---|---|---|---|---|
|CTMX|CTMX.O|CytomX Therapeutics|2024 Q1|2.2052E7|4.1463E7|1.3791E7|185|
|CTMX|CTMX.O|CytomX Therapeutics|2024 Q2|2.5172E7|2.5115E7|-6534000|185|
|CTMX|CTMX.O|CytomX Therapeutics|2024 Q3|2.1368E7|3.3432E7|5736000|185|
|CTMX|CTMX.O|CytomX Therapeutics|2024 Q4|1.479E7|3.8093E7|1.8876E7|185|

</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw){return {layout:"default",data:[{noData:c,currentQuestion:g,textDescription:V,comeFrom:"AInvestShareLink",events:[],answerSource:o}],fetch:{},error:p,state:{sharePreviewModule:{loadJgySuccess:d,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:h,agent_id:a,output_media_info:[],task_id:a,language:a,source:o,cache_builder:a,reply_action:"Answer",execute_mode:I,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did CytomX Therapeutics' revenue and expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did CytomX Therapeutics' revenue and expenses trend in Q4 2024?\",\"user_id\":\"dp94558866\",\"user_name\":\"\",\"trace_id\":\"00f7ecf5-ad49-40da-bbf1-8d4a8debb118\",\"session_id\":\"00f7ecf5-ad49-40da-bbf1-8d4a8debb118\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:j,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue[20241231]|R&D Expenses[20241231]|Total Expenses[20241231]|Net Income[20241231]|Report End Date|\n|---|---|---|---|---|---|---|---|---|\n|CTMX|CytomX Therapeutics|$0.97|0.54%|$38.09 million|$14.79 million||$18.88 million|20241231|\n",query_data:{number:h,title:J,query_type:j,condition:a,model_sql:W,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d}}}],answer_chain_name:X,agent_mode:Y,native_answer:a,come_from:a,text_answer:V,trace_id:i,cost:18920,event_names:a,question:g,fallback_type:Z,input_type:_,fall_back_reason:{fall_back_type:Z,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:i,first_return_cost:3628,cache_type:"no_cache",question_id:i,transfer_question:g,signal_type:"ON_COMPLETE",start_time:$,remote_svc:o,slots:[],answer_type:I,user_id:z,skill_name:K},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:z,question:g,source:o,raw_question:g,version:"3.4.1",action_name:K,nlu:{entity:[{type:aa,value:q,market:k}]},deep_research:c,deep_thinking:c,agent_mode:Y},extra:{}},{answer_path:A,section:{id:B,info_texts:["Thinking"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:A,section:{id:B,info_texts:["Querying Stock: CTMX Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:J,thought:"The user seeks to analyze CytomX Therapeutics' Q4 2024 revenue and expense trends. I should focus on its Q4 2024 revenue, R&D expenses, SG&A expenses, and net income data. I will use FinQuery for the data mentioned above."}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:A,section:{id:B,info_texts:["Generating Answer"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:D,voice_txt:"C",text_answer:ab,rich_text:ab,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:2000,info_texts:[],show_type:D,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:J,query_type:j,trace_data:a,index:h,model_sql:W,data_ext_params:{merge_repeat:c,expand_index:b,data_add:h,add_index:d},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:r,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:D,voice_txt:".\n\n",text_answer:ac,rich_text:ac,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:t,market_id:k,name:m,domain:aa},pos:d,section_id:s,txt:m,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:ad,choice:[],result_page:{components:[{uuid:"349792803cca2d2d",config:{score:116,show_type:ae,scoreRuleNames:"value_unit;data_size;",showDataZoom:b,show_type_id:131,title:"分组柱状图",render:{x:u,y:[E,F,G]},title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:af,h2:a},show_type:L}},data:{chunks_info:"[]",code_count:h,columns:[{index_name:M,key:M,label:"hq_code",source:N,type:f},{domain:v,feKey:O,index_name:O,key:O,label:M,origin_index:"stock code",source:N,type:f,unit:a},{domain:v,feKey:P,index_name:P,key:P,label:"name",origin_index:"stock name",source:N,type:f,unit:a},{feKey:u,index_name:u,key:u,label:"date",origin_index:u,type:"DATE"},{domain:v,feKey:E,index_name:E,key:E,label:a,source:a,timestamp:a,type:Q,unit:R},{domain:v,feKey:F,index_name:F,key:F,label:a,source:a,timestamp:a,type:Q,unit:R},{domain:v,feKey:G,index_name:G,key:G,label:a,source:a,timestamp:a,type:Q,unit:R},{index_name:ag,key:ag,type:f}],condition:"[{\"sonSize\":6,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL CTMX.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"CTMX.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":4,\"opName\":\"or\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@R\\u0026D Expenses\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Net Income\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@Total Revenue\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:4,datas:[{"Net Income":13791000,code:t,"R&D Expenses":22052000,"Total Revenue":41463000,Ticker:q,market_code:k,Date:"2024 Q1",Name:m},{"Net Income":-6534000,code:t,"R&D Expenses":25172000,"Total Revenue":25115000,Ticker:q,market_code:k,Date:"2024 Q2",Name:m},{"Net Income":5736000,code:t,"R&D Expenses":21368000,"Total Revenue":33432000,Ticker:q,market_code:k,Date:"2024 Q3",Name:m},{"Net Income":18876000,code:t,"R&D Expenses":14790000,"Total Revenue":38093000,Ticker:q,market_code:k,Date:"2024 Q4",Name:m}],meta:{extra:{}},row_count:h,status_code:d,status_msg:"ok"},category:"generic",chart_type:"groupedBar",show_type:ae,title_config:{config:{display:b,display2:c,txt_style:d,url:a},data:{h1:af,h2:a},show_type:L},support_refresh:b,data_config:{query:a,query_type:j,data_ext_params:{}}}],global:{query_type:j},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"bar3\",\"uuid\":\"349792803cca2d2d\"}]"},render_for:S},data_config:{query:a,query_type:j,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"a6f48a12-4f76-442f-944c-7ad0b53eaec3"},logs:[],extra:{}},{answer_path:e,section:{id:s,info_texts:[],show_type:D,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:A,section:{id:B,info_texts:["Completed"],show_type:C,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:ad,choice:[{display_text:w,query_text:w,trace_info:{item_id:"24849d4b9f75ea4d1ada0af29a473b16",item_type:n,item_name:w,rec_info:ah}},{display_text:x,query_text:x,trace_info:{item_id:"8989b5091dec941924321f918c05df1e",item_type:n,item_name:x,rec_info:ai}},{display_text:y,query_text:y,trace_info:{item_id:"b511dfcb7fffdc5bca8807f9a6291051",item_type:n,item_name:y,rec_info:aj}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:L,data:{h1:a,h2:a},config:{display:c,txt_style:d,type:"1",display2:c,url:a}},request_config:[{source_type:ak,related_name:al}],puuid:T,tag:a,category:"custom",uuid:am}],global:{urp_static_data:[{name:al,value:{status_code:d,columns:[{type:f,index_name:an,key:an},{type:f,index_name:ao,key:ao},{type:f,index_name:ap,key:ap},{type:f,index_name:aq,key:aq},{type:f,index_name:ar,key:ar}],datas:[{send_text:w,item_type:n,rec_info:ah,display_text:w,rec_reason:a},{send_text:x,item_type:n,rec_info:ai,display_text:x,rec_reason:a},{send_text:y,item_type:n,rec_info:aj,display_text:y,rec_reason:a}],dataSize:ak,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:as,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:H,"min-height":"100%",position:at,height:H},isMaterial:c,id:as,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:d,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:U,componentUuid:am,script:[{name:au,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:U,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:U},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:H,position:at,height:H},isMaterial:b,_id:19,id:au,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:S,voice_txt:a,tracking_info:{},uuid:T},order:{is_auto:c,render_for:S,chart_type:"command",puuid:T}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:K,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:I,answer_chain_name:X},is_deep_research:c,deep_thinking:c,create_time:1746613951122},is_last:b}],questionItem:{data:{qStr:g,encodeFlag:c,imageData:p,docsData:[],quoteData:p},tplType:"question"},events:av,agentId:a,param:{entity_info:{},add_info:{ori_question:g},event_list:av,client_ip:a,question:g,user_id:z,user_name:a,trace_id:i,session_id:i,source:o,input_type:_}}],userId:z,userName:a,startTime:$,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:p,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:d,traceTableData:p,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-cytomx-therapeutics-revenue-and-expenses-trend-in-q4-2024-40664f\u002F",config:{_app:{basePath:aw,assetsPath:aw,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,0,"other\u002FopenAnswer","STR","How did CytomX Therapeutics' revenue and expenses trend in Q4 2024?",1,"00f7ecf5-ad49-40da-bbf1-8d4a8debb118","intusstock","185","signal","CytomX Therapeutics","llm_generated","ths_ainvest_lite_web",null,"CTMX.O",999,2001,"CTMX","Date","abs_国际美股领域","What were CytomX Therapeutics' revenue figures for Q4 2024?","What was the net income or loss for CytomX Therapeutics in Q4 2024?","How does CytomX Therapeutics' Q4 2024 financial performance compare to analyst expectations?","dp94558866","progress\u002Fsearching_for",1000,"searching_for","rich_text","R&D Expenses","Total Revenue","Net Income","auto","agent","CTMX Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)","inspect stocks","title1","code","fixed_index","Ticker","Name","DOUBLE","USD","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","CytomX Therapeutics' revenue and expenses in Q4 2024 showed a revenue of $38.09 million and total expenses of $18.88 million, with $14.79 million being R&D expenses.\n\n\n|code|Ticker|Name|Date|R&D Expenses|Total Revenue|Net Income|market_code|\n|---|---|---|---|---|---|---|---|\n|CTMX|CTMX.O|CytomX Therapeutics|2024 Q1|2.2052E7|4.1463E7|1.3791E7|185|\n|CTMX|CTMX.O|CytomX Therapeutics|2024 Q2|2.5172E7|2.5115E7|-6534000|185|\n|CTMX|CTMX.O|CytomX Therapeutics|2024 Q3|2.1368E7|3.3432E7|5736000|185|\n|CTMX|CTMX.O|CytomX Therapeutics|2024 Q4|1.479E7|3.8093E7|1.8876E7|185|\n\n","select   stock_code,   total_revenue,   r_d_expenses,   total_expenses,   net_income from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'CTMX.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1746613932202,"stock","CytomX Therapeutics' revenue and expenses in Q4 2024 showed a revenue of $38.09 million and total expenses of $18.88 million, with $14.79 million being R&D expenses[^1]",".\n\n\n``` visual\n{\"uuid\":\"a6f48a12-4f76-442f-944c-7ad0b53eaec3\"}\n```","result_page","bar3","CTMX R&D Expenses, Total Revenue...","market_code","2+679_496_21_554+0+0+00f7ecf5-ad49-40da-bbf1-8d4a8debb118+24849d4b9f75ea4d1ada0af29a473b16+llm_generated+aimeTagAnalysis+0+0.06502895057201385+1","2+679_496_21_554+0+0+00f7ecf5-ad49-40da-bbf1-8d4a8debb118+8989b5091dec941924321f918c05df1e+llm_generated+aimeTagAnalysis+0+0.041151244193315506+2","2+679_496_21_554+0+0+00f7ecf5-ad49-40da-bbf1-8d4a8debb118+b511dfcb7fffdc5bca8807f9a6291051+llm_generated+aimeTagAnalysis+0+0.017210712656378746+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>